The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Next-generation covalent BTKis in the CLL treatment landscape
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses next-generation covalent BTK inhibitors (BTKis) for the treatment of chronic lymphocytic leukemia (CLL). She highlights that zanubrutinib and acalabrutinib have a more selective inhibition profile compared to the first-generation BTKi ibrutinib. This selectivity is expected to provide similar efficacy with fewer adverse events (AEs), particularly in reducing cardiotoxicity. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory Board: AbbVie, AstraZeneca, BeiGene, Janssen, Lilly, Merck; Speaker bureau: OctaPharma.
